Immuno Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 9.80 M
- Company Age 45 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.49 Cr
- Revenue Growth 0.23%
- Profit Growth -24.54%
- Ebitda -21.56%
- Net Worth 16.74%
- Total Assets 14.84%
About Immuno Diagnostics
Immuno Diagnostics Pvt Ltd (IDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 November 1979 and has a history of 45 years and three months. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.80 M.
The company currently has active open charges totaling ₹5.49 Cr.
Apoorva Chaudhary, Ajay Kumar, and Neera Choudhary serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74899DL1979PTC009991
- Company No.
009991
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 1979
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Immuno Diagnostics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apoorva Chaudhary  | Director | 02-Apr-2019 | Current |
| Ajay Kumar | Director | 08-Aug-2002 | Current |
| Neera Choudhary | Director | 08-Aug-2002 | Current |
Financial Performance of Immuno Diagnostics.
Immuno Diagnostics Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 0.23% increase. The company also saw a substantial fall in profitability, with a 24.54% decrease in profit. The company's net worth Soared by an impressive increase of 16.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immuno Diagnostics?
In 2023, Immuno Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.49 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 5.20 Cr
- Hdfc Bank Limited : 0.29 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Oct 2023 | Hdfc Bank Limited | ₹2.94 M | Open |
| 26 Jul 2023 | Canara Bank | ₹2.00 Cr | Open |
| 16 Sep 2021 | Canara Bank | ₹3.10 Cr | Open |
| 22 Sep 2006 | Canara Bank | ₹0.95 M | Open |
How Many Employees Work at Immuno Diagnostics?
Immuno Diagnostics has a workforce of 66 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immuno Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immuno Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.